Literature DB >> 19214510

Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms.

Domenica Caramazza1, Clementina Caracciolo, Rita Barone, Alessandra Malato, Giorgia Saccullo, Valeria Cigna, Salvatore Berretta, Luciana Schinocca, Gerlando Quintini, Vincenzo Abbadessa, Francesco Di Raimondo, Sergio Siragusa.   

Abstract

The evidence that leukocytes may contribute to the pathogenesis of thrombosis in Chronic Myeloproliferative Neoplasms is increasing but not definitive. To further enforces whether an increased leukocyte count is associated with thrombosis and whether this effect can be modulated by cytoreductive therapy, we analyzed the clinical course of 187 patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) followed at two Italian Institutions over a period of 7 years. The association was measured at diagnosis or before thrombotic events: a multivariable analysis was carried out using data at baseline and time-dependent covariates. We found that white blood cells (WBC) count above 9.5 x 10(9)/L at diagnosis (baseline analysis) was associated with thrombosis during the follow-up (Hazard Ratio [HR] of 1.8, p 0.03). At the time-dependent analysis, therapy with hydroxyurea (HU), lowering by 35% the baseline WBC level, reduced such strength of association giving a HR of 1.3 (p value non significant). We found a trend between WBC level and thrombosis in untreated low-risk patients (RR of 1.9, 95% CI 0.9 to 3.1); in high-risk patients treated with HU this correlation was clearly lost (RR 1.1, 95% CI 0.2 to 2.7). Finally, we could not identify the presence of JAK2 (V617F) as a risk factor for thrombosis. Properly designed prospective studies should corroborate such results.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19214510     DOI: 10.1007/s00277-009-0706-x

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  8 in total

1.  Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?

Authors:  Tiziano Barbui; Alessandra Carobbio; Alessandro Rambaldi; Guido Finazzi
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

2.  Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.

Authors:  Alessandra Carobbio; Alberto Ferrari; Arianna Masciulli; Arianna Ghirardi; Giovanni Barosi; Tiziano Barbui
Journal:  Blood Adv       Date:  2019-06-11

Review 3.  SOHO State-of-the-Art Update and Next Questions: MPN.

Authors:  Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01

Review 4.  How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.

Authors:  Andreas Reiter; Claire Harrison
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

Review 5.  Mechanisms of thrombogenesis in polycythemia vera.

Authors:  Michael H Kroll; Laura C Michaelis; Srdan Verstovsek
Journal:  Blood Rev       Date:  2014-12-13       Impact factor: 8.250

6.  Perturbation of the developmental potential of preimplantation mouse embryos by hydroxyurea.

Authors:  Mariam Sampson; Anthony E Archibong; Adriane Powell; Brandon Strange; Shannon Roberson; Edward R Hills; Phillip Bourne
Journal:  Int J Environ Res Public Health       Date:  2010-04-28       Impact factor: 3.390

Review 7.  Clinical and hematological presentation of children and adolescents with polycythemia vera.

Authors:  Holger Cario; Mary Frances McMullin; Heike L Pahl
Journal:  Ann Hematol       Date:  2009-05-26       Impact factor: 3.673

8.  A case report of cerebral infarction caused by polycythemia vera.

Authors:  Shan Ren; Fang Gao; Zhigang Chen; Zhiqun Wang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.